Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Diagnostic rates and risk factors for the subsequent development of chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary embolism (PE) are not well defined.

Methods: Over a 10-year period (2010-2020), consecutive patients attending a PE follow-up clinic in Sheffield, UK (population 554 600) and all patients diagnosed with CTEPH at a pulmonary hypertension (PH) referral centre in Sheffield (referral population estimated 15-20 million) were included.

Results: Of 1956 patients attending the Sheffield PE clinic 3 months following a diagnosis of acute PE, 41 were diagnosed with CTEPH with a cumulative incidence of 2.10%, with 1.89% diagnosed within 2 years. Of 809 patients presenting with pulmonary hypertension (PH) and diagnosed with CTEPH, 32 were Sheffield residents and 777 were non-Sheffield residents. Patients diagnosed with CTEPH at the PE follow-up clinic had shorter symptom duration (p<0.01), better exercise capacity (p<0.05) and less severe pulmonary haemodynamics (p<0.01) compared with patients referred with suspected PH. Patients with no major transient risk factors present at the time of acute PE had a significantly higher risk of CTEPH compared with patients with major transient risk factors (OR 3.6, 95% CI 1.11-11.91; p=0.03). The presence of three computed tomography (CT) features of PH in combination with two or more out of four features of chronic thromboembolic pulmonary disease at the index PE was found in 19% of patients who developed CTEPH and in 0% of patients who did not. Diagnostic rates and pulmonary endarterectomy (PEA) rates were higher at 13.2 and 3.6 per million per year, respectively, for Sheffield residents compared with 3.9-5.2 and 1.7-2.3 per million per year, respectively, for non-Sheffield residents.

Conclusions: In the real-world setting a dedicated PE follow-up pathway identifies patients with less severe CTEPH and increases population-based CTEPH diagnostic and PEA rates. At the time of acute PE diagnosis the absence of major transient risk factors, CT features of PH and chronic thromboembolism are risk factors for a subsequent diagnosis of CTEPH.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7615743PMC
http://dx.doi.org/10.1183/13993003.00846-2023DOI Listing

Publication Analysis

Top Keywords

pulmonary hypertension
16
diagnosed cteph
16
pulmonary embolism
8
diagnostic rates
8
chronic thromboembolic
8
thromboembolic pulmonary
8
cteph pulmonary
8
patients attending
8
follow-up clinic
8
patients diagnosed
8

Similar Publications

Application of stereotactic radiotherapy in the treatment of cardiovascular diseases through sympathectomy.

Zhong Nan Da Xue Xue Bao Yi Xue Ban

May 2025

Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.

Sympathectomy, as an emerging treatment method for cardiovascular diseases, has received extensive attention in recent years. Stereotactic radiotherapy (SRT), a precise and noninvasive therapeutic technique, has gradually been introduced into interventions targeting the sympathetic nervous system and has shown promising prospects in the management of cardiovascular conditions. Using three-dimensional imaging, SRT can accurately localize sympathetic ganglia and deliver high-energy radiation to disrupt nerve fibers, thereby achieving effects similar to conventional sympathectomy while reducing surgery-related complications and shortening recovery time.

View Article and Find Full Text PDF

Background: Tetrandrine (TET) demonstrates therapeutic potential for hypoxic pulmonary hypertension (HPH); however, its precise pharmacological mechanisms remain unclear. In this study, we aimed to investigate the effects of TET on pulmonary vascular remodeling (PVR) in HPH and elucidate the molecular pathways through which TET ameliorates HPH.

Methods: We established a rat model of HPH and evaluated the therapeutic effects of TET by measuring hemodynamic parameters, assessing right ventricular hypertrophy, and analyzing pathological changes in lung tissue.

View Article and Find Full Text PDF

Background: Pulmonary Hypertension (PH) is a significant contributor to cardiac mortality in Dilated Cardiomyopathy (DCM) patients. Inflammatory processes and oxidative stress play pivotal roles in the advancement of Pulmonary Hypertension (PH). The Monocyte-to-High-- Density-Lipoprotein Cholesterol Ratio (MHR), a newly identified biomarker indicative of inflammatory and oxidative stress, has not been extensively researched in the context of pulmonary hypertension, especially within the scope of dilated cardiomyopathy.

View Article and Find Full Text PDF

Background: Pulmonary hypertension is associated with cardiovascular events, but when assessed at rest, it has limited sensitivity. Pulmonary vascular reserve can be assessed noninvasively using exercise echocardiography, but this has not been studied in adults with coarctation of aorta (COA). We hypothesized that adults with COA had worse pulmonary vascular reserve compared to controls, and that impaired pulmonary vascular reserve was associated with clinical indices of disease severity independent right ventricular (RV) indices at rest.

View Article and Find Full Text PDF

Pulmonary arterial hypertension (PAH) is a rare but serious disease that poses a significant threat to patients' quality of life and life expectancy. Perfluorooctane sulfonate (PFOS) is a widely used chemical that, due to its toxicity, persistence, and bioaccumulation properties, may increase the risk of developing PAH with prolonged exposure. This study investigated the molecular mechanisms linking PFOS exposure to PAH by integrating network toxicology and molecular docking methods.

View Article and Find Full Text PDF